As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is courting foreign investment as well, including from drugmakers.

Earlier this month, Ian Lipkin, M.D., and his team at Columbia University submitted a paper for publication that suggests certain approved drugs could possibly be repurposed for a severe fatigue condition that currently has no approved treatment, while also highlighting prospective targets for new therapeutics. A week later, the NIH terminated grant funding to Columbia's center studying the condition.

Over the last three years, the FDA has approved six new drugs for hemophilia. And now the U.S. regulator has signed off on another, Sanofi’s Qfitlia, which sets itself apart as the only treatment for all types of hemophilia.

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since he took the reins in 2019. O’Day received a compensation package of $23.7 million last year, a 5% boost on his $22.6 million pay from 2023.

CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the company’s executive team. Bruno had been with CRISPR for six years, serving in several management roles with increasing responsibility before landing the chief operating officer position last May.

BioNTech has shown why it made small cell lung cancer a priority for its PD-L1xVEGF-A bispecific. The biotech linked BNT327 to a median overall survival of 16.8 months in a Chinese phase 2 trial, suggesting the drug candidate could set a new benchmark in a market served by AstraZeneca and Roche.

Visby's kit includes vaginal self-collection swabs and a palm-sized, PCR-based testing device for chlamydia, gonorrhea and trichomoniasis, which delivers a result within 30 minutes.

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease med Kisunla also got a rejection from EU regulators.

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic antibodies while eking out its cash to cover a slew of clinical readouts over the next couple of years.